Effects of metformin on patients with polycystic ovary syndrome and its effect on adipose tissue miR-25 level

doi:10.12092/j.issn.1009-2501.2019.05.012

Abstract

Abstract:

AIM: To analyze the effect of metformin on patients with polycystic ovary syndrome (PCOS) and its effect on adipose tissue miR-25 level. METHODS: From March 2018 to January 2019, 76 patients with PCOS were enrolled in the department of endocrinology and gynecology in our hospital. The simple randomization method was used to divide them into two groups, 38 cases in each group. The control group was given ethinyl estradiol progesterone tablets. The observation group was given metformin on the basis of this, and the total effective rate, sex hormone binding protein (SHBG), luteinizing hormone (LH), testosterone (T), follicle stimulating hormone (FSH), and female two were compared after treatment for 6 courses. Alcohol (E2), fasting insulin (FINS), insulin resistance index (HOMA-IR), waist-to-hip ratio (WHR), body mass index (BMI), adipose tissue miR-25 mRNA level were counted. RESULTS:After treatment for 6 courses, the total effective rate was 94.74% higher than that of the control group (76.32%) (P<0.05). After 6 courses of treatment, SHBG in the observation group increased more significantly than that in the control group, while LH, T, FINS, HOMA-IR, WHR and BMI decreased more significantly than that in the control group (P<0.05). There was no significant difference in FSH and E2 between the two groups after 6 courses of treatment (P>0.05); after 6 courses of treatment, the expression of microRNA-25 in the observation group decreased more significantly than that in the control group (P<0.05).CONCLUSION:Metformin treatment of PCOS can improve the level of sex hormones and central obesity, correct endocrine abnormalities and increase insulin sensitivity. The mechanism may be related to the inhibition of miR-25 expression in adipose tissue. miR-25 targeting inhibitor provides new idea for treating PCOS.

Key words: adipose tissue, metformin, miR-25, polycystic ovary syndrome, efficacy

CLC Number:

GUO Liangtang, LIN Chao, SUN Yun, DAI Shengfeng, ZHANG Bingcai, CHEN Shu. Effects of metformin on patients with polycystic ovary syndrome and its effect on adipose tissue miR-25 level[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 554-560.

References

［1］金武敏,林佳,王佩玉,等.非降调促排卵方案在多囊卵巢综合征患者行体外授精-胚胎移植治疗中的疗效比较［J］.中国临床药理学与治疗学,2016,21(10):1178-1184.
［2］Cadagan D,Khan R,Amer S.Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome［J］.Reprod Biol,2016,16(1):53-60.
［3］Paul C,Laganà AS,Maniglio P,et al.Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome:state-of-the-art and future perspectives［J］.Gynecol Endocrinol,2016,32(6):431-438.
［4］陈雅,叶碧绿,郑九嘉,等.血清及卵泡液抗苗勒管激素在多囊卵巢综合征患者体外受精促排卵治疗中的价值［J］.中国临床药理学与治疗学,2015,20(12):1405-1411.
［5］吕立群,李薇.多囊卵巢综合征合并胰岛素抵抗患者脂肪组织瘦素信号转导分子-JAK2和STAT3蛋白的表达及磷酸化研究［J］.中国妇幼保健,2016,31(19):3922-3925.
［6］Yuan X,Hu T,Zhao H,et al.Brown adipose tissue transplantation ameliorates polycystic ovary syndrome［J］.Proc Natl Acad Sci U S A,2016,113(10):2708-13.
［7］郭良堂,戴凌虹,陈红,等.多囊卵巢综合征患者脂肪组织miR-25和微小染色体维持蛋白7的表达水平及临床意义［J］.中国妇幼保健,2018,33(24):5943-5946.
［8］乐杰.妇产科学［M］.第7版.北京:人民卫生出版社,2008:316.
［9］刘金铃.达英35治疗多囊卵巢综合征的疗效评价［J］.中国实用医药,2017,12(23):130-131.
［10］Cree-Green M,Rahat H,Newcomer BR,et al.Insulin resistance, hyperinsulinemia, and mitochondria dysfunction in nonobese girls with polycystic ovarian syndrome［J］.J Endocr Soc,2017,1(7):931-944.
［11］Song DK, Hong YS,Sung YA,et al.Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance［J］.Plos One,2017,12(5):e0178120.
［12］Gültepe I,Basaranoglu M,Süleymano?lu Y,et al.Ovaries are more vulnerable than hepatocytes for insulin resistance and hyperinsulinemia［J］.Turk J Gastroenterol,2016,27(1):62-67.
［13］高金金,侯丽辉,李妍,等.体质量指数正常的多囊卵巢综合征伴胰岛素抵抗患者的临床特征及胰岛素抵抗影响因素分析［J］.实用妇产科杂志,2017,33(03):46-49.
［14］程玲慧,李泽莲,颜士杰,等.胰岛素抵抗对多囊卵巢综合征育龄妇女生育能力的影响［J］.中国临床保健杂志,2016,19(2):163-165.
［15］荣晅,宋东峰,侯春丽,等.胰岛素抵抗对多囊卵巢综合征患者内分泌及卵巢形态的影响［J］.广西医科大学学报,2017,34(8):1149-1152.
［16］徐岚,熊煜.炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征患者排卵的影响［J］.中国药房,2016,27(24):3368-3370.
［17］熊苗,朱海润,罗艳群,等.炔雌醇环丙孕酮片对PCOS患者血清抗苗勒氏管激素的影响［J］.现代妇产科进展,2018,27(03):195-197.
［18］张郡,宿宓,许良智,等.炔雌醇环丙孕酮片与去氧孕烯炔雌醇片的长期应用对多囊卵巢综合征的疗效及代谢安全性［J］.南方医科大学学报,2018,38(08):917-922.
［19］张彩宇,陶爱群,莫有珍.二甲双胍与炔雌醇环丙孕酮片联用对多囊卵巢综合征患者相关激素分泌水平的影响［J］.中国现代医学杂志,2016,26(9):85-88.
［20］秦凤,李春亮,张惠莉.二甲双胍对2型糖尿病模型大鼠胰岛素抵抗的影响［J］.中国组织工程研究,2017,21(12):1909-1914.
［21］赵晓兰,冯琳.二甲双胍联合维格列汀对多囊卵巢综合征合并糖代谢异常的临床疗效研究［J］.中国临床药理学杂志,2016,32(6):517-519.
［22］岳欣,全会标.多囊卵巢综合征患者性激素水平与胰岛素抵抗的相关性研究［J］.安徽医药,2016,20(2):386-388.
［23］Stener-Victorin E,Maliqueo M,Soligo M,et al.Changes in HbA1cand circulating and adipose tissue androgen levels in overweight‐obese women with polycystic ovary syndrome in response to electroacupuncture［J］.Obes Sci Pract,2016,2(4):426-435.
［24］Alshammari G,Khan R,Brameld J,et al.Gene expression of inflammatory markers in adipose tissue between obese women with polycystic ovary and normal obese women［J］.Eur Rev Med Pharmacol Sci,2017,21(5):1099-1105.
［25］Delitala AP,Capobianco G,Delitala G,et al.Polycystic ovary syndrome, adipose tissue and metabolic syndrome［J］.Arch Gynecol Obstet,2017,296(3):405-419.
［26］Nakamitsu PZ,Compri CM,de Fraia Pinto L,et al.Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice［J］.Endocr Metab Immune Disord Drug Target,2015,15(2):151-158.
［27］Slutsky N,Vatarescu M,Haim Y,et al.Decreased adiponectin links elevated adipose tissue autophagy with adipocyte endocrine dysfunction in obesity［J］.Int J Obes(Lond),2016,40(6):912-920.
［28］Magliano DC,Penna-de-carvalho A,Vazquez-carrera M,et al.Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system［J］.Endocrine,2015,50(2):355-367.
［29］支翠菊,黄瑛,祁炜罡,等.microRNA在肥胖大鼠脂肪组织中的差异表达［J］.中西医结合心脑血管病杂志,2017,15(1):40-43.
［30］Hossain MM,Cao M,Wang Q,et a1.Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model［J］.J Ovarian Res,2013,6(1):36.
［31］Setyowati Karolina D,Sepramaniam S,Tan HZ,et al.miR-25 and miR-92a regulate insulin Ibiosynthesis in rats［J］.RNA Biol,2013,10(8):1365-1378.
［32］Wu HL,Heneidi S,Chuang TY,et al.The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome［J］.J Clin Endocrinol Metab,2014,99(12):E2754-2761.
［33］Sirotkin AV,Ovcharenko D,Grossmann R,et al.Identification of MicroRNAs controlling human ovarian cell steroidogenesis via a genome‐scale screen［J］.J Cell Physiol,2010,219(2):415-420.
［34］Zhang H,Zuo Z,Lu X,et al.MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer［J］.Oncol Rep,2011,27(2):594-598.
［35］Petrocca F,Vecchione A,Croce CM.Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling［J］.Cancer Res,2008,68(20):8191-8194.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[4]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[5]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[6]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[7]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[8]	DU Chen, TIAN He, CAO Yang, WANG Yongjun, ZHANG Yan. Research progress on bone metabolism disorders associated with PCOS elucidated from endocrine hormones [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 328-333.
[9]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[10]	HAO Wei, ZUO Dongze, ZHANG Junxiu, JIANG Lili, XIONG Ying, YANG Jieren. Effects of metformin on epithelial-mesenchymal transition of rat alveolar epithelial type II cells induced by TGF-β1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 744-752.
[11]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[12]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.
[13]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[14]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[15]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.